Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T ... Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs. 더 보기
Atara received FDA Complete Response Letter (CRL) solely related to inspection findings at third-party manufacturer CRL did not identify deficiencies related to clinical efficacy or safety data...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -9.3401 | -58.3027465668 | 16.02 | 17.8316 | 6.52 | 648110 | 9.81312898 | CS |
4 | -3.7501 | -35.9549376798 | 10.43 | 18.705 | 6.52 | 294212 | 11.57388778 | CS |
12 | -1.8701 | -21.8725146199 | 8.55 | 18.705 | 6.52 | 163872 | 11.44604799 | CS |
26 | -5.7601 | -46.3030546624 | 12.44 | 18.705 | 6.5 | 136348 | 10.10728835 | CS |
52 | -11.0726 | -62.3720602732 | 17.7525 | 39.5 | 6.5 | 995073 | 19.50401062 | CS |
156 | -388.8201 | -98.3110240202 | 395.5 | 408.75 | 4.965 | 1639237 | 65.59521432 | CS |
260 | -395.3201 | -98.3383333333 | 402 | 705 | 4.965 | 1340784 | 147.16704245 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관